查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2009114

气喘治疗市场规模、份额、趋势和预测：按药物类别、产品类型、治疗方法、给药途径和地区划分，2026-2034 年

Asthma Therapeutics Market Size, Share, Trends and Forecast by Drug Class, Product Type, Treatment Type, Route of Administration, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2025年全球气喘治疗市场规模为191.6亿美元。展望未来，IMARC集团预测，该市场将以1.73%的复合年增长率从2026年增长至2034年，到2034年达到224.9亿美元。目前，北美市场占据主导地位，预计2025年将占全球市场份额的47.3%。该地区拥有完善的医疗保健基础设施、较高的呼吸系统疾病发病率以及健全的法规结构，这些优势有利于先进气喘治疗方案的快速核准和推广，从而巩固了其在全球气喘治疗市场的份额。

全球气喘治疗市场受多种因素共同驱动：呼吸系统疾病负担日益加重、慢性呼吸道管理意识不断提高以及药物输送系统的快速发展。儿童和成人气喘盛行率的不断上升，推动了对有效且标靶治疗方法的需求。生物製药和单株抗体的广泛应用，拓展了治疗选择，使中重度气喘患者能够获得更个人化和精准的治疗方案。此外，全球老年人口的成长（老年人患呼吸系统疾病的风险更高）也进一步促进了多个地区气喘治疗市场的成长。

由于多种因素，美国正崛起为气喘治疗市场的重要区域。美国是世界上气喘盛行率最高的国家之一，相当一部分人口需要持续的治疗管理。美国肺臟协会报告称，美国有2,680万成年人和450万儿童患有气喘，凸显了对持续治疗和疾病管理的广泛需求。这种持续的需求推动了市场的活跃发展，包括处方药、先进的给药装置和生物製药。吸入型皮质类固醇和长效β2受体激动剂的广泛应用反映了医师对现有治疗方案的信心。此外，美国完善的医疗保健体系，包括广泛的保险覆盖、活跃的医生网络和患者支持项目，正在扩大气喘治疗的可及性。

气喘治疗市场趋势：

生物製药的应用日益广泛

生物製药的日益普及标誌着重症气喘治疗的变革性转变，尤其适用于对传统治疗方法反应不佳的患者。这些治疗方法对嗜酸性粒细胞或过敏性气喘患者特别有益，使医护人员能够根据特定患者的疾病特征提供更有针对性和个人化的干预措施。 2025年12月，美国食品药物管理局（FDA）核准了葛兰素史克（GSK）开发的depemokimab（Exdensur）作为重症嗜酸性粒细胞气喘的附加维持治疗生物製药。这是该类别中首个获准的、每年两次给药的生物製药。随着皮下和静脉注射途径的增加，这些治疗方法的应用范围正从住院患者扩展到门诊病人。

智慧吸入器技术的进步

智慧吸入器技术的快速普及正在从根本上改变全球不同患者群体的气喘管理方式。这些数位化设备整合了电子感测器和连接功能，能够监控用药模式、追踪吸入技巧，并将即时数据传输到行动平台上的相关应用程式。资讯来源显示，使用智慧吸入器的患者的用药依从率达到71.4%，而传统治疗组的依从率为59.9%，这显示智慧吸入器技术能够显着提高气喘治疗的依从性。监管机构对数位健康工具的支持以及智慧设备报销途径的开发，正在推动气喘治疗市场的发展，因为该领域正在采用先进的、技术主导的护理模式，这些模式有望显着提高患者的用药依从性和长期呼吸系统健康状况。

联合治疗的作用日益增强

联合治疗在气喘管理中的作用日益增强，正在显着改变全球临床治疗通讯协定。将不同药理类别的药物合併使用，例如吸入性糖皮质激素与长效β2受体激动剂或白三烯受体拮抗剂，可以产生单一药物治疗无法达到的协同效应。 2024年5月，世界卫生组织（WHO）报告称，全球约有2.62亿人患有气喘，每年约有45.5万人死于气喘，凸显了开发更有效的治疗策略（包括联合治疗）的必要性。此外，持续进行的探索新型联合治疗的临床研究以及全球市场保险报销范围的扩大，都为气喘治疗市场带来了乐观前景，推动着该行业朝着提供日益全面和循证的呼吸系统护理方向发展。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球气喘治疗市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依药物类别划分

  • 抗发炎药
  • 支气管扩张剂
  • 联合治疗

第七章 市场区隔：依产品类型划分

  • 吸入器
    • 主要类型
      • 干粉吸入器
      • 定量喷雾吸入器
      • 缓雾吸入器
  • 喷雾器
    • 主要类型
      • 气动雾化器
      • 超音波雾化器
      • 网状雾化器

第八章 市场区隔：依治疗类型划分

  • 快速起效的药物
  • 长期气喘管理药物

第九章 市场区隔：依给药途径

  • 吸入
  • 口服
  • 肠外

第十章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 SWOT 分析

第十二章：价值链分析

第十三章：波特五力分析

第十四章：价格分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • AstraZeneca PLC
    • Abbott Laboratories
    • Amgen Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck Sharp & Dohme Corp.
    • Novartis International AG
    • Sunovion Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A2338

The global asthma therapeutics market size was valued at USD 19.16 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 22.49 Billion by 2034, exhibiting a CAGR of 1.73% from 2026-2034. North America currently dominates the market, holding a market share of 47.3% in 2025. The region benefits from an extensive healthcare infrastructure, high prevalence of respiratory disorders, and robust regulatory frameworks that facilitate the timely approval and adoption of advanced asthma therapeutic solutions, reinforcing the global asthma therapeutics market share.

The global asthma therapeutics market is driven by a confluence of rising respiratory disease burden, growing awareness of chronic airway management, and rapid advancements in drug delivery systems. An increasing global prevalence of asthma among both pediatric and adult populations has intensified the demand for effective and targeted treatment regimens. The widespread adoption of biologics and monoclonal antibodies has expanded the treatment landscape, enabling more personalized and precision-based therapeutic approaches for patients with moderate to severe asthma. The expanding geriatric population globally, which tends to exhibit higher susceptibility to respiratory ailments, is additionally supporting asthma therapeutics market growth across multiple geographies.

The United States has emerged as a major region in the asthma therapeutics market owing to many factors. The nation carries one of the highest burdens of asthma globally, with a substantial portion of its population requiring continuous therapeutic management. According to reports, the American Lung Association reported that 26.8 million adults and 4.5 million children are living with asthma, emphasizing the widespread need for consistent treatment and disease management. This persistent demand has fueled robust market activity encompassing prescription medications, advanced delivery devices, and biologics. The widespread acceptance of inhaled corticosteroids and long-acting beta-agonists reflects physician confidence in established therapeutic pathways. Additionally, well-developed healthcare systems characterized by widespread insurance coverage, active physician networks, and patient support programs are enabling broader access to asthma medications.

ASTHMA THERAPEUTICS MARKET TRENDS:

Rising Adoption of Biologic Therapies

The growing adoption of biologic therapies represents a transformative shift in the management of severe asthma, particularly for patients who do not respond adequately to conventional treatment approaches. These therapies are especially beneficial for patients with eosinophilic or allergic phenotypes of asthma, enabling healthcare providers to deliver more targeted and individualized interventions based on specific patient disease profiles. In December 2025, the U.S. Food and Drug Administration approved depemokimab (Exdensur), developed by GSK, as an add-on maintenance biologic therapy for severe eosinophilic asthma, becoming the first biologic in this category designed for twice-yearly dosing. The increased availability of subcutaneous and intravenous administration options has expanded the reach of these treatments across hospital and outpatient settings alike.

Advancements in Smart Inhaler Technology

The rapid proliferation of smart inhaler technologies is fundamentally redefining asthma management practices across diverse patient demographics worldwide. These digitally enabled devices integrate electronic sensors and connectivity features that monitor medication usage patterns, track inhalation technique, and transmit real-time data to companion applications on mobile platforms. As per sources, that digital inhaler users achieved 71.4% medication adherence compared with 59.9% in standard-care groups, demonstrating improved asthma treatment compliance through connected inhaler technologies. Regulatory support for digital health tools and evolving reimbursement pathways for connected devices is reinforcing the asthma therapeutics market outlook as the sector embraces advanced, technology-driven care models promising meaningful improvements in patient adherence and long-term respiratory health outcomes.

Expanding Role of Combination Therapies

The expanding role of combination therapies in asthma management is significantly reshaping treatment protocols across clinical settings worldwide. Combining agents from different pharmacological classes, such as inhaled corticosteroids with long-acting beta-agonists or leukotriene receptor antagonists, offers synergistic benefits that single-agent therapies often cannot achieve independently. In May 2024, the World Health Organization reported that asthma affected around 262 million people globally and caused approximately 455 000 deaths annually, emphasizing the need for more effective treatment strategies including combination therapies. Furthermore, ongoing clinical investigations examining additional combination options, together with expanding reimbursement support across global markets, continue to underpin the positive asthma therapeutics market forecast as the industry advances toward increasingly holistic and evidence-based respiratory care delivery.

ASTHMA THERAPEUTICS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

  • Anti-Inflammatory Drugs
  • Bronchodilators
  • Combination Therapies

Anti-inflammatory drugs hold 62.8% of the market share, representing the foundational therapeutic category in asthma management, encompassing inhaled corticosteroids, leukotriene modifiers, and newer biologic agents designed to suppress airway inflammation at its source. These medications function by targeting the underlying inflammatory mechanisms responsible for airway hyperresponsiveness, mucus hypersecretion, and progressive bronchoconstriction, delivering meaningful symptomatic relief and reducing the risk of acute exacerbations. Inhaled corticosteroids, which constitute the primary subcategory, are widely recommended as first-line treatment across international asthma management guidelines due to their well-established safety and efficacy profiles. The emergence of biologic agents within the anti-inflammatory drug class has further expanded therapeutic options for patients with difficult-to-control and severe asthma phenotypes, enabling more precise targeting of specific immune pathways. Rising physician adoption of phenotype-guided treatment strategies continues to accelerate prescriptions within this category. Broader awareness of evolving asthma therapeutics market trends is encouraging healthcare systems to increasingly prioritize preventive anti-inflammatory therapies over reactive management approaches worldwide.

Analysis by Product Type:

  • Inhalers
    • Dry Powder Inhalers
    • Metered Dose Inhalers
    • Soft Mist Inhalers
  • Nebulizers
    • Pneumatic Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers

Inhalers lead the market with a share of 68.5%, offering a direct-to-lung drug delivery mechanism that maximizes therapeutic efficacy while minimizing systemic side effects. The category encompasses a diverse range of device types, including dry powder inhalers, metered dose inhalers, and soft mist inhalers, each designed to accommodate varying patient preferences, inhalation capacities, and severity levels. Metered dose inhalers remain the most widely used device type globally, given their portability, ease of use, and broad compatibility with multiple drug formulations including corticosteroids, bronchodilators, and combination therapies. As per sources, Viatris and Kindeva Drug Delivery launched Breyna(TM), the first U.S. FDA-approved generic version of Symbicort, a budesonide-formoterol inhalation aerosol used for asthma and COPD treatment. Dry powder inhalers are gaining traction owing to their propellant-free design and growing alignment with environmental sustainability initiatives across the pharmaceutical sector. Soft mist inhalers offer additional advantages for patients with coordination difficulties by producing a slow-moving aerosol cloud that optimizes lung deposition.

Analysis by Treatment Type:

  • Quick-Relief Medications
  • Long-Term Asthma Control Medications

Long-term asthma control medications dominate the market, with a share of 58.5%, encompassing a broad spectrum of therapies designed to reduce airway inflammation, prevent bronchoconstriction, and minimize the frequency and severity of asthma exacerbations over an extended period. These medications, which include inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, and biologic agents, are prescribed as maintenance therapy for patients with persistent asthma. Their primary objective is to achieve and sustain asthma control, reducing the need for rescue medications and emergency interventions. Healthcare guidelines across major markets consistently recommend long-term control medications as the cornerstone of chronic asthma management, given their demonstrated ability to improve quality of life and reduce hospitalizations. The proliferation of biologics within this category has introduced highly targeted treatment options that address specific disease phenotypes, further strengthening clinical outcomes. Increased awareness of proactive disease management and the growing emphasis on personalized medicine are supporting sustained expansion of this treatment category globally.

Analysis by Route of Administration:

  • Inhalation
  • Oral
  • Parenteral

Inhalation represents the leading segment, with a market share of 72.5%, as a route of administration is firmly established as the preferred delivery mechanism for asthma therapeutics worldwide, primarily due to its ability to deliver drugs directly to the site of action within the airways with high precision and minimal systemic exposure. This targeted approach significantly reduces the risk of systemic adverse effects commonly associated with oral or parenteral routes while enabling rapid onset of therapeutic action, making it particularly suitable for both maintenance and rescue therapy. The availability of a wide variety of inhaled formulations, including corticosteroids, bronchodilators, and combination products, supports comprehensive disease management across all severity levels. Technological advances in inhaler design, such as the development of more patient-friendly devices with dose counters, breath-actuation features, and digital connectivity, have further reinforced the dominance of the inhalation route.

REGIONAL ANALYSIS:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 47.3% of the share, maintaining the leading position in the market. The regions commanding position in the asthma therapeutics landscape is underpinned by a well-established healthcare infrastructure, a high disease burden, and a sophisticated pharmaceutical ecosystem that facilitates rapid adoption of innovative therapies. The region is home to the world's largest and most advanced healthcare markets, supported by substantial public and private investment in respiratory medicine research and development. Favorable regulatory pathways managed by agencies such as the U.S. Food and Drug Administration have historically enabled timely market entry for new drug approvals, including biologics and novel inhaler technologies. Comprehensive health insurance coverage and reimbursement structures across the United States and Canada have further expanded patient access to a broad spectrum of asthma therapies. Growing awareness of disease management best practices, robust clinical trial activity, and a strong pipeline of investigational asthma therapies are collectively sustaining the region's leadership position within the global market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ASTHMA THERAPEUTICS MARKET ANALYSIS

The region has the largest national market in terms of the total market size in the global asthma therapeutics industry. This is attributed to the exceptionally high prevalence rates of the disease in the country. Additionally, the country has an entrenched tradition of pharmaceutical innovation and healthcare accessibility. It has an extensive healthcare system that includes well-organized networks of physicians, pulmonologists, and well-funded research activities that ensure continuous innovation in the detection and treatment of the disease. Government agencies like the national institutes of health and the centers for disease control and prevention actively monitor the epidemiology of the disease. They fund research activities that seek to improve treatment outcomes. The adoption of guidelines by organizations like the National asthma education and prevention program has helped standardize treatment approaches. This ensures that patients receive consistent treatment, including the prescription of drugs, despite their demographics. The country has an entrenched system of health insurance that covers patients suffering from asthma. This has helped remove economic barriers to treatment. Organizations advocating for patients suffering from the disease, along with active public awareness campaigns, have helped improve patient recognition, early detection, and treatment adherence.

EUROPE ASTHMA THERAPEUTICS MARKET ANALYSIS

Europe represents a well-developed and strategically significant market for asthma therapeutics, characterized by high healthcare standards, universal insurance coverage in most member states, and strong governmental emphasis on respiratory health. The region exhibits a significant asthma burden across densely populated nations such as Germany, France, the United Kingdom, and Italy, where environmental factors including urbanization, air pollution, and allergen exposure contribute to persistently high prevalence rates. According to reports, the European Commission approved Tezspire (tezepelumab), developed by AstraZeneca, as an add-on maintenance treatment for patients aged 12 years and older with severe asthma inadequately controlled by high-dose inhaled corticosteroids and another therapy. The national health service model prevalent across many European nations supports universal access to asthma medications, reducing out-of-pocket costs for patients. Growing investment in digital health adoption, telemedicine infrastructure, and personalized medicine initiatives is advancing asthma management capabilities across the continent. Additionally, pan-European public health programs focused on early diagnosis, preventive care, and patient education are supporting better disease control and contributing to sustained demand for advanced asthma therapeutics.

ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET ANALYSIS

Asia-Pacific represents a rapidly growing market for asthma therapeutics, driven by a large population base, rising urbanization, and increasing prevalence of respiratory conditions across the region. Countries such as China, India, Japan, South Korea, and Australia are experiencing escalating asthma burdens attributable to worsening air quality, occupational exposures, and changing environmental conditions. Government-led healthcare expansion initiatives and increasing investment in pharmaceutical infrastructure are improving access to asthma medications in previously underserved areas. The growing middle class in emerging economies such as India and China is driving greater healthcare consumption, including increased utilization of branded and innovative asthma therapeutic products. Additionally, rising physician awareness of modern treatment protocols and expanding health insurance coverage are translating into improved diagnosis rates and stronger demand for effective, long-term asthma management solutions across both urban and rural populations.

LATIN AMERICA ASTHMA THERAPEUTICS MARKET ANALYSIS

Latin America presents a growing market for asthma therapeutics, supported by rising disease prevalence, improving healthcare access, and expanding pharmaceutical distribution networks. Brazil and Mexico serve as the primary market contributors in the region, driven by large patient populations, ongoing government healthcare investments, and strengthening insurance frameworks. Increasing urbanization and environmental degradation are elevating asthma incidence across the region. Regional health authorities are advancing public awareness campaigns to promote early diagnosis and consistent treatment adherence, further generating demand for therapeutic solutions. Nonetheless, affordability remains a key factor influencing treatment accessibility for a significant proportion of the Latin American patient population.

MIDDLE EAST AND AFRICA ASTHMA THERAPEUTICS MARKET ANALYSIS

The Middle East and Africa region represents an emerging market for asthma therapeutics, with demand driven by high disease prevalence rooted in environmental, climatic, and occupational risk factors across the region. Countries in the Gulf Cooperation Council, including Saudi Arabia and the United Arab Emirates, are making significant strides in healthcare infrastructure development and pharmaceutical market expansion. Increasing government investment in respiratory health programs and rising health awareness among the population are supporting market growth. However, limited healthcare access and affordability constraints in parts of sub-Saharan Africa continue to temper the overall pace of market development across the broader region.

COMPETITIVE LANDSCAPE:

The asthma therapeutics market is characterized by intense competitive activity among a select group of multinational pharmaceutical corporations that collectively dominate global drug development, manufacturing, and commercialization efforts. Market participants are actively engaged in advancing proprietary pipelines of biologic agents, inhaled corticosteroids, and novel combination therapies to address increasingly complex patient needs. Strategic collaborations, licensing agreements, and joint research initiatives are commonly employed to accelerate the progression of candidate molecules through clinical development phases. Companies are also investing substantially in device innovation, particularly in the development of smart inhalers and digitally enabled respiratory management platforms that align with evolving patient expectations and regulatory priorities.

The report provides a comprehensive analysis of the competitive landscape in the asthma therapeutics market with detailed profiles of all major companies, including:

  • AstraZeneca PLC
  • Abbott Laboratories
  • Amgen Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp.
  • Novartis International AG
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the asthma therapeutics market?

2. What is the future outlook of the asthma therapeutics market?

3. What are the key factors driving the asthma therapeutics market?

4. Which region accounts for the largest asthma therapeutics market share?

5. Which are the leading companies in the global asthma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Asthma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Anti-Inflammatory Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bronchodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Combination Therapies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Inhalers
    • 7.1.1 Market Trends
    • 7.1.2 Major Types
      • 7.1.2.1 Dry Powder Inhalers
      • 7.1.2.2 Metered Dose Inhalers
      • 7.1.2.3 Soft Mist Inhalers
    • 7.1.3 Market Forecast
  • 7.2 Nebulizers
    • 7.2.1 Market Trends
    • 7.2.2 Major Types
      • 7.2.2.1 Pneumatic Nebulizers
      • 7.2.2.2 Ultrasonic Nebulizers
      • 7.2.2.3 Mesh Nebulizers
    • 7.2.3 Market Forecast

8 Market Breakup by Treatment Type

  • 8.1 Quick-Relief Medications
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Long-Term Asthma Control Medications
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Inhalation
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Parenteral
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AstraZeneca PLC
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Abbott Laboratories
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Boehringer Ingelheim International GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 F. Hoffmann-La Roche Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck Sharp & Dohme Corp.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis International AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sunovion Pharmaceuticals Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 SWOT Analysis
    • 15.3.11 Teva Pharmaceutical Industries Ltd.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Asthma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Asthma Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Asthma Therapeutics Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Asthma Therapeutics Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Asthma Therapeutics Market: Breakup by Treatment Type (in %), 2025
  • Figure 6: Global: Asthma Therapeutics Market: Breakup by Route of Administration (in %), 2025
  • Figure 7: Global: Asthma Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Asthma Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Asthma Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Asthma Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Asthma Therapeutics (Combination Therapies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Asthma Therapeutics (Combination Therapies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Asthma Therapeutics (Inhalers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Asthma Therapeutics (Inhalers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Asthma Therapeutics (Nebulizers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Asthma Therapeutics (Nebulizers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Asthma Therapeutics (Quick-Relief Medications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Asthma Therapeutics (Quick-Relief Medications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Asthma Therapeutics (Inhalation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Asthma Therapeutics (Inhalation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Asthma Therapeutics (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Asthma Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Asthma Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Asthma Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia Pacific: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia Pacific: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Asthma Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Asthma Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Asthma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Asthma Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Asthma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Asthma Therapeutics Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 4: Global: Asthma Therapeutics Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 5: Global: Asthma Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 6: Global: Asthma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Asthma Therapeutics Market Structure
  • Table 8: Global: Asthma Therapeutics Market: Key Players